Navigation Links
FDA Warns Against Certain Uses of Asthma Drug Terbutaline for Preterm Labor
Date:2/17/2011

SILVER SPRING, Md., Feb. 17, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration is warning that terbutaline administered by injection or through an infusion pump should not be used in pregnant women for prevention or prolonged (beyond 48-72 hours) treatment of preterm labor due to the potential for serious maternal heart problems and death. In addition, oral terbutaline tablets should not be used for prevention or treatment of preterm labor. The FDA is requiring the addition of a Boxed Warning and Contraindication to the drug prescribing information (labeling) to warn against these uses.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Terbutaline is FDA-approved to prevent and treat narrowing of the airways (bronchospasm) associated with asthma, bronchitis, and emphysema. The drug is used off-label for obstetric purposes, including treating preterm labor and treating uterine hyperstimulation. Terbutaline has also been used in an attempt to prevent recurrent preterm labor. There is no evidence, however, that use of terbutaline to prevent preterm labor improves infant outcomes. Serious adverse events, including maternal deaths, have been reported with such use in pregnant patients.

"Women should be aware that serious and sometimes fatal side effects have been reported after prolonged use of terbutaline in pregnant women," said Scott Monroe, M.D., director of FDA's Division of Reproductive and Urologic Products. "It is important for patients and health care professionals to consider all the potential risks and known benefits of any drug before deciding on its use."

The FDA is aware that administration of terbutaline by injection to pregnant women is used in hospital settings in certain urgent situations. The FDA warning relates to safety concerns about the prolonged use of terbutaline injection beyond 48-72 hours, and against any use of oral terbutaline in pregnant women for prevention or treatment of preterm labor.

The decision to require a Boxed Warning and Contraindication is based on the FDA's review of post-market safety reports of heart problems and even death associated with terbutaline use for obstetric indications, as well as data from medical literature documenting the lack of safety and effectiveness of terbutaline for preventing preterm labor, and animal data suggesting potential risks. Based on this information, the FDA concluded that the risk of serious adverse events outweighs any potential benefit to pregnant patients for either prolonged use of terbutaline injection beyond 48-72 hours or use of oral terbutaline for prevention or treatment of preterm labor.

These changes to the drug labeling are consistent with statements from the American College of Obstetricians and Gynecologists discouraging use of terbutaline for preventing preterm labor.

There are multiple generic versions of terbutaline oral tablets and injectable formulations available. The brand name products were previously discontinued by the companies that made them.  

The FDA encourages patients to talk to their health care professional if they have concerns about any treatment they are receiving. Patients and health care professionals should report any side effects from the use of terbutaline to the FDA's MedWatch adverse event reporting program at www.fda.gov/MedWatch.

For more information:

Drug Safety Communication: Use of Terbutaline for Preterm Labor

http://www.fda.gov/Drugs/DrugSafety/ucm243539.htm

FDA Citizen Petition Response: Terbutaline Sulfate, Docket No. FDA-2008-P-0358

http://www.fda.gov/downloads/Drugs/DrugSafety/UCM243797.pdf

Media Inquiries: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Agriculture Department Warns Consumers of Tainted Raw Milk Sold by Chester County Dairy
2. Agriculture Department Warns Consumers of Tainted Raw Milk Sold by Lebanon County Dairy
3. New Federal Stem Cell Rules Would Hinder Existing Research, Consumer Group Warns
4. Orkin Warns of Four Pests to Avoid this Fourth of July
5. FDA Warns Consumers about Counterfeit Alli
6. Toxic Chemical bisphenol A Still Not Banned By FDA; Schumer, Gillibrand Call for Ban; Govt Official Warns Public
7. Physicians Foundation Warns of Potential Impact From New Medicare Cuts Effective Today
8. H.E.A.T. Warns Drivers, Auto Dealers of Continuing Trend in Unconventional Auto Crimes
9. FDA Warns Users About Faulty Components in 14 External Defibrillator Models
10. FDA Warns About Fraudulent Tamiflu
11. FDA Warns Consumers to Avoid TimeOut Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... , June 8, 2017  Less than a month ... more than 200,000 companies, including hospital networks, in over ... as one of the largest online extortion attempts ever ... healthcare market, it is imperative that providers understand where ... data from this — and many other very real ...
(Date:6/7/2017)... Iowa , June 6, 2017  Diplomat Specialty Infusion Group, ... sterile compounding environment to its Iowa location. ... Urbandale now features an ISO 7 cleanroom—the standard ... controlled environment with a low level of pollutants. ... more IV nutrition consumers and better serve our Iowa ...
(Date:6/1/2017)... 1, 2017 Nutriceutical Holdings (NH), parent company ... (VRS), and KD Pharma Group have decided to join ... KD Pharma Group. KD Pharma Group will become the ... acquire the entire company. "We believe we ... committed to growing the NH companies by providing us ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... ... All-Star Insurance, a family managed agency that offers insurance management assistance and personal ... of a new charity drive to benefit women in the area diagnosed with breast ... estimated 252, 710 new cases of invasive or high risk breast cancer will be ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... 2017 , ... Despite its pervasiveness, many physicians are unfamiliar with how best ... with clinical practice. Now, however, a timely review has been published in the ... etiology of NeuP and educating preclinical scientists on its diagnosis and choice of treatment. ...
(Date:6/22/2017)... ... June 23, 2017 , ... Rise Against Hunger ... June 21, 2017, at the Emeryville Center of Community Life. More than 374 ... world. , Rise Against Hunger (formerly Stop Hunger Now) meal packaging events are ...
(Date:6/20/2017)... , ... June 20, 2017 , ... After months of negotiations, FaceCradle USA is proud ... on Wednesday, June 21. , “Introducing our product on QVC is something we all ... promote our travel pillow to more than 90 million homes in the United States,” said ...
Breaking Medicine News(10 mins):